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Abstract
Objective—Patients with Parkinson disease (PD) and mild cognitive impairment (MCI) are 
vulnerable to dementia and frequently experience memory deficits. This could be the result of 
dopamine dysfunction in corticostriatal networks (salience, central executive networks, and 
striatum) and/or the medial temporal lobe. Our aim was to investigate whether dopamine 
dysfunction in these regions contributes to memory impairment in PD.
Methods—We used positron emission tomography imaging to compare D2 receptor availability 
in the cortex and striatal (limbic and associative) dopamine neuron integrity in 4 groups: memory-
impaired PD (amnestic MCI; n=9), PD with nonamnestic MCI (n=10), PD without MCI (n=11), 
and healthy controls (n=14). Subjects were administered a full neuropsychological test battery for 
cognitive performance.
Results—Memory-impaired patients demonstrated more significant reductions in D2 receptor 
binding in the salience network (insular cortex and anterior cingulate cortex [ACC] and the right 
parahippocampal gyrus [PHG]) compared to healthy controls and patients with no MCI. They also 
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presented reductions in the right insula and right ACC compared to nonamnestic MCI patients. D2 
levels were correlated with memory performance in the right PHG and left insula of amnestic 
patients and with executive performance in the bilateral insula and left ACC of all MCI patients. 
Associative striatal dopamine denervation was significant in all PD patients.
Interpretation—Dopaminergic differences in the salience network and the medial temporal lobe 
contribute to memory impairment in PD. Furthermore, these findings indicate the vulnerability of 
the salience network in PD and its potential role in memory and executive dysfunction.
Throughout daily life, new memories are formed and past memories are constantly drawn 
upon to guide behavior. Parkinson disease (PD) patients often experience memory deficits 
characterized by the inability to recall information, and memory impairment is a significant 
predictor of future dementia.1,2 Dopamine (DA) transmission is known to be crucial to 
normal memory function. DA signaling in the striatum facilitates learning, 3 and 
mesocorticolimbic DA modulates memory consolidation and retrieval in both the medial 
temporal lobe and cortex.4,5 Recently, we demonstrated that striatal DA depletion in a region 
involved in cognitive processing (associative striatum) as well as D2 receptor reductions in 
the bilateral insula contribute to executive dysfunction in PD.6 However, the contribution of 
dopaminergic dysfunction to memory impairment remains unclear. The insula along with the 
anterior cingulate cortex (ACC) is part of a salience network, known to causally influence 
activation and enable switching between the central executive network7 and the default mode 
network, 8,9 which cooperate to facilitate memory.10,11 It has been suggested that memory 
deficits in PD may be the result of dysfunctional executive networks that participate in 
memory retrieval and organization.12–15 Thus, due to their roles in executive processing, 
dopaminergic dysfunction in the salience network, the central executive network, or the 
striatum, which is highly interconnected with these cortical regions,16,17 could have a 
profound impact on memory. Alternatively, there is evidence that points to memory deficits 
in PD as the result of DA dysfunction in the medial temporal lobe,18,19 suggesting that 
memory impairment may be the result of abnormal encoding or storage of memory. The aim 
of this study was to assess whether dopaminergic differences in (1) the central executive 
network, salience network, or striatum or (2) the medial temporal lobe contribute to memory 
deficits in PD patients with mild cognitive impairment (MCI). We used positron emission 
tomography (PET) imaging to examine cortical D2 receptor availability in the dorsolateral 
prefrontal cortex (DLPFC) and posterior parietal cortex (PPC; central executive network); 
the insula and ACC (salience network); and the medial temporal lobe, as well as DA neuron 
integrity in the striatum in a sample of PD patients with significant memory impairment, as 
assessed by a full neuropsychological test battery. Furthermore, we aimed to determine 
whether dopaminergic changes could explain variance in memory performance, and whether 
changes related to memory and executive dysfunction coincide in the brain.
Subjects and Methods
Participants and Experimental Design
There were 44 subjects in total; 30 PD patients meeting the UK Parkinson Disease Society 
Brain Bank Criteria and 14 aged-matched healthy controls participated in the study (Table 
1). Participants had no evidence of other neurological or psychiatric conditions. Patients 
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meeting the criteria for dementia were excluded.20 All participants were matched for age 
and years of education and patients were matched for disease severity as measured by the 
Unified Parkinson Disease Rating Scale III (UPDRS-III) and for L-dopa equivalent daily 
dose (LEDD). The LEDD is based on theoretical equivalence to L-dopa using the following 
formula: L-dopa dose+L-dopa dose × ⅓ if on entacapone+bromocriptine (mg) × 
10+cabergoline or pramipexole (mg) × 67+ropinirole (mg) × 20+pergolide (mg) × 
100+apomorphine (mg) × 8.21 All participants received a neuropsychological assessment on 
medication to assess cognitive status and healthy controls showed no evidence of cognitive 
impairment (Table 2).
Participants were also screened for depression using the Beck Depression Inventory.22 
Patients withdrew from antiparkinsonian medication for 12 hours prior to the PET scans. 
Participants were scanned with [11C]FLB 457, a D2 receptor ligand, which is used to 
measure D2 binding in cortical regions, and provides an accurate assessment of 
dopaminergic function in the human cortex. Participants were also scanned with 
[11C]dihydrotetrabenazine (DTBZ), a radioligand binding to vesicular monoamine 
transporter (VMAT2), which is a biomarker for DA neuron integrity in the striatum. VMAT2 
is the present gold standard marker for DA neuron integrity and is well established as a 
method for measuring DA neuron degeneration in the striatum in PD.23–26 Subjects also 
underwent a high-resolution structural magnetic resonance imaging (MRI) scan for 
registration with the PET images. Both PET scans and MRI scans were performed on 
separate days to avoid excessive fatigue. Neuropsychological testing was performed within 6 
months of PET scans to ensure no significant change in cognitive status. Some data from a 
smaller sample of these subjects have been reported previously.6 This study was approved by 
the research ethics committees for the Centre for Addiction and Mental Health and the 
University Health Network of the University of Toronto. All subjects provided written 
informed consent to participate.
Neuropsychological Assessment
Patients were diagnosed as PD with MCI according the recent Movement Disorders 
Society–commissioned task force criteria. 27 Patients were classified as PD-MCI according 
to the level II criteria requiring at least 1.5 standard deviations below the normative mean on 
at least 2 core variables of tests in a full neuropsychological test battery. The level II criteria 
were used, as opposed to level I, to provide more detailed neuropsychological test data for 
further subtyping of PD patients with MCI into amnestic (memory impaired) and 
nonamnestic types. All subjects were administered the full neuropsychological test battery, 
which requires the inclusion of at least 2 tests in each cognitive domain (memory, executive 
function, attention/working memory, language, visuospatial function). Core variables from 
each test were selected for use in the diagnosis of PD-MCI. The Disability Assessment for 
Dementia was used to ensure that no patients had any functional impairment due to 
cognition. 28 The neuropsychological test variables included the Wechsler Memory Scale III 
Digit Span (attention) and Letter-Number Sequencing total score (attention/working 
memory),29 California Verbal Learning Test II (CVLT-II) long delay free recall score 
(memory),30 Visual Verbal Test total number of shifts (executive),31 Judgment of Line 
Orientation total score (visuospatial),32 Delis–Kaplan Executive Function System (D-KEFS) 
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Color-Word Interference, time to complete condition 1: color naming (attention), D-KEFS 
Color-Word Interference, time to complete condition 3: inhibition (executive), D-KEFS 
Verbal Fluency, total score for category fluency (language/executive), 33 Rey Complex 
Figure Test (RCFT) copy score (visuospatial), RCFT long delay recall score (visuospatial 
memory),34 Trail-Making Test (condition B-A) difference score (executive), and 30-Item 
Boston Naming Test, total score (language).35 All raw scores were converted into z-scores. 
To split PD patients into nonamnestic and amnestic subtypes, we created composite z-scores 
for memory performance by taking the mean of the core variables for memory, CVLT 
delayed recall and RCFT delayed recall, which have previously been used to create 
composite scores for episodic memory performance.36 A median split was used to divide PD 
patients with MCI into those with high and low memory performance to ensure that patients 
classified as amnestic MCI had the lowest overall memory performance. 37 All 
neuropsychological data including memory scores for the 4 groups are displayed in Table 2. 
For assessing relationships between PET imaging measures and our cognitive domains of 
interest, composite z-scores were calculated. For executive function the mean of the z-scores 
from the Visual Verbal Test, inhibition segment of the Color-Word Interference task, verbal 
(semantic) fluency, and difference score from the Trail-Making Test were used. The average 
of the z-scores from the CVLT long delay free recall and RCFT delayed recall were used as 
a measure of declarative memory function. The healthy control sample reported in our 
previous imaging study6 was assessed using a more limited neuropsychological test battery 
that did not include the RCFT, Trail-Making Test, or 30-Item Boston Naming Test.
PET Imaging
PET scanning was performed using a 3-dimensional (3D) high-resolution research 
tomograph (HRRT) brain tomograph (Siemens, Knoxville, TN), which measures 
radioactivity in 207 brain sections with a thickness of 1.22 mm each. The detectors of the 
HRRT are a lutetium oxyorthosilicate/lutetium–yttrium oxyorthosilicate phoswich detector, 
with each crystal element measuring 2 × 2 × 10 mm3. A 10-minute transmission scan, 
measured using a single photon point source, 137Cs (t1/2=30.2 years, Eγ=662keV) was 
acquired immediately before the acquisition of the emission scan to correct for attenuation. 
Custom-made thermoplastic facemasks together with a head-fixation system (Tru-Scan 
Imaging, Annapolis, MD) were used to minimize subject head movement in the scanner. 
Upon completion of the acquisition, the emission list mode data were rebinned into a series 
of 3D sinograms. For each 3D sinogram, the data were normalized with attenuation and 
scatter correction before applying Fourier rebinning to convert the 3D sinograms into 2D 
sinograms.38 The 2D sinograms were then reconstructed into image space using a 2D 
filtered back projection algorithm, with a ramp filter at Nyquist cutoff frequency. Each 
subject underwent a [11C]DTBZ and [11C]FLB 457 PET scan on separate days. For each 
scan, the radioactive tracer was injected as a bolus into an intravenous line placed in an 
antecubital vein. Emission data were acquired over 90 minutes for [11C]FLB 457 and 60 
minutes for [11C]DTBZ while subjects were at rest. Subjects underwent an MRI scan on a 
separate day to obtain high-resolution T1-weighted and proton density–weighted structural 
MRIs. The MR scans were performed on a GE Discovery MR750 3.0T scanner (Milwaukee, 
WI, USA) equipped with an 8-channel head coil.
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Methods are the same as those employed in our previous imaging study.6 High-resolution 
T1-weighted MRIs (GE Discovery MR750 3.0T, 0.9 mm slice thickness) of each subject’s 
brain were transformed into standardized stereotaxic space using nonlinear automated 
feature matching to the Montreal Neurological Institute (MNI) template.39 PET frames were 
smoothed, realigned, summed, and registered to the subject MRI.40 The coregistered MRI 
and PET were transformed into standardized stereotaxic space using transformation 
parameters of the individual MRI scans. PET images were smoothed with an isotropic 
Gaussian kernel of 6 mm full width at half maximum (FWHM). Voxelwise [11C]FLB 457 
nondisplaceable binding potential (BPND) was estimated using the simplified reference 
tissue model (SRTM) with the cerebellum as a reference region41,42 to generate statistical 
parametric images of BPND change.43
STATISTICAL ANALYSIS—Statistical maps were constructed demonstrating voxel-by-
voxel BPND changes in MATLAB v7.4 (Mathworks, Natick, MA) using Statistical 
Parametric Mapping software (SPM8; Wellcome Department of Imaging Neuroscience, 
London, UK). [11C]FLB 457 BPND was compared across groups using an analysis of 
covariance (ANCOVA) in SPM8 for significant effects of group controlling for covariates 
including age, disease severity (UPDRS-III), and LEDD, followed by voxelwise post hoc 
independent sample t tests to examine between-group differences (SPM8). T-map images 
were thresholded at p<0.05 with an extent threshold of k=10. All coordinates of significant 
clusters are reported in MNI space. Correction within our a priori regions of interest used 
small volume correction for the specified brain region. Regions of changes in BPND at the 
extrastriatal level were considered significant at the voxel level threshold of p<0.05 after 
familywise error (FWE) correction for multiple comparisons. Voxelwise multiple regression 
analysis with composite z-scores for memory and executive function from the 
neuropsychological test battery was performed to determine whether there was a relationship 
between cognitive functions in these domains and the amount of D2 receptor binding. 
UPDRS-III and LEDD were used as covariates in the analysis to control for disease severity 
and medication effects on BPND as an outcome measure.
[11C]DTBZ Analysis
Methods were the same as those employed in previous studies. 6,44 Region of interest (ROI) 
analysis was performed for [11C]DTBZ to measure BPND. Analysis is similar to that 
described in Rusjan et al,45 using ROMI software (based on Talairach and Kabani atlases).
46,47 Our striatal ROIs included the associative striatum (anterior putamen and caudate 
nucleus), sensorimotor, and limbic striatal subdivisions. These were delineated according to 
previously specified criteria.45,48 A standard brain template (International Consortium for 
Brain Mapping/Montreal Neurological Institute 152 MRI) containing predefined subcortical 
ROIs was nonlinearly transformed using SPM8 to the individual MRI (GE Discovery 
MR750 3.0T, proton density–weighted images, 2mm slice thickness). Individual ROIs were 
aligned and resliced to register with the PET images using a normalized mutual information 
algorithm. The occipital cortex was used as a reference region due to the lack of significant 
VMAT2 in this region.49 [11C]DTBZ BPND was obtained in each ROI using the SRTM41,42 
with the occipital cortex time–activity curve as an input function50,51 using Receptor 
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Parametric Mapping software. To address possible confounding effects of atrophy in the PD 
patient groups, partial volume effect correction was implemented using the Rousset 
algorithm.52
STATISTICAL ANALYSIS—A multivariate ANCOVA was used to compare [11C]DTBZ 
across groups of subjects in each striatal ROI while controlling for age, motor disease 
severity (UPDRS-III), and LEDD. Post hoc independent sample t tests were used to test for 
differences between groups using SPSS (v13.0; IBM, Armonk, NY) software. Results were 
considered significant at the threshold of p<0.05, corrected for multiple comparisons 
(Bonferroni).
Cortical Thickness Analysis
Cortical thickness analysis was used to investigate whether there was significant cortical 
thinning in our cortical regions of interest for the [11C]FLB 457 analysis using FreeSurfer 
software (v4.0.5, freely available at: http://surfer.nmr.mgh.harvard.edu).53,54 This software is 
a widely used, automated program for the analysis of brain structure.55 In brief, removal of 
non-brain tissue is followed by the segmentation of gray and white matter, and then 
alignment of each image volume to a standardized space (ie, MNI space). After intensity 
normalization, gray and white tissue segmentation was used as the starting point for a 
deformable surface algorithm that was applied to extract the pial and gray/white surfaces to 
estimate cortical thickness.53 Cortical thickness was calculated as the closest distance from 
the gray/white boundary to the gray matter/cerebrospinal fluid boundary at each vertex on 
the tessellated surface.55
STATISTICAL ANALYSIS—Differences between groups were assessed using a vertex-by-
vertex general linear model. The model included cortical thickness as a dependent factor, 
group as an independent factor, and also included age, LEDD, and UPDRS-III as nuisances 
variables (https://surfer.nmr.mgh.harvard.edu/fswiki/FsgdFormat). Resulting maps were 
smoothed using a Gaussian kernel with an FWHM of 15mm. Monte Carlo Z simulations 
with 10,000 iterations were applied to cortical thickness maps for clusterwise correction for 
multiple comparisons. Results were thresholded at a probability value of 0.05 (z=1.3) 
corrected for multiple comparisons.
Results
D2 Receptors in Cortical Brain Networks and Memory
First, we aimed to investigate whether there were significant group differences in DA D2 
receptors in the DLPFC, PPC, insula, ACC, or medial temporal lobe (the regions defined in 
our a priori hypothesis). We found a significant difference in D2 receptor availability 
between the 4 groups in the bilateral ACC, insula, and right parahippocampal gyrus (PHG; 
F2,30=8.43, p=0.01). Voxelwise t tests demonstrated a reduction in D2 receptor availability 
in the PD patients with amnestic MCI in the right PHG, bilateral insula, and ACC compared 
to healthy controls (p<0.05, Supplementary Table 1). Patients with nonamnestic MCI also 
demonstrated reductions in D2 availability compared to healthy controls in the right PHG 
and bilateral ACC, although less severe compared to the amnestic group (p<0.05, 
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Supplementary Table 2). When comparing the MCI groups to PD patients with no MCI, the 
memory-impaired group had significant reductions in D2 in the right PHG and bilateral 
insula. They also showed a trend toward reduced binding in the left ACC; however, this did 
not reach significance with FWE correction (Fig 1, Supplementary Table 3). The 
nonamnestic MCI group only had a significant reduction in the left insula (p=0.03) and a 
trend toward reduction in the right insula (p=0.05) compared to patients without MCI (see 
Fig 1, Supplementary Table 4). Lastly, when contrasting the 2 MCI groups, PD patients with 
memory impairment demonstrated significantly reduced D2 in the right ACC (p=0.04) and 
right insula (p=0.028), as well as a trend toward reduced binding in the left ACC (p=0.07, 
Supplementary Table 5). Mean binding potential values extracted from each of our a priori 
regions of interest are displayed in Table 3. Importantly, memory was the only cognitive 
domain in which the amnestic MCI group displayed significantly worse performance than 
the nonamnestic MCI group. However, because our regions of interest included executive 
networks, we added executive composite z-score as a nuisance variable in the comparison 
between PD groups to ensure that changes seen in the amnestic MCI group were not 
confounded by worsening executive function. The changes in D2 receptor levels remained 
significant after controlling for executive composite z-score, suggesting that the group 
differences are independently associated with memory impairment in these regions. Notably, 
there was no significant difference in D2 binding between healthy controls and patients with 
no MCI, signifying that D2 reductions were unique to patients with cognitive impairment.
Striatal DA Depletion and Memory
Additionally, we aimed to determine whether striatal DA nerve terminal integrity, as 
measured with [11C]DTBZ, was related to memory impairment in PD patients in the 
associative and limbic striatum, the subdivisions involved in the modulation of memory. We 
found significant differences in [11C]DTBZ binding between groups in the associative 
striatum that remained significant after controlling for age, motor disease severity, and daily 
dopaminergic medication intake (F2,30=7.582, p < 0.0001). Post hoc independent sample t 
tests demonstrated that compared to healthy controls, significantly reduced binding was 
found in the PD without MCI group (p=0.005) as well as PD patients with nonamnestic MCI 
(p<0.0001) and PD patients with amnestic MCI (p<0.0001), indicative of severe DA neuron 
degeneration in all PD patient groups (Fig 2). When comparing patients with PD, the 
patients with amnestic MCI had significantly reduced DA neuron integrity compared to PD 
patients with no MCI (p=0.016, see Fig 2). We demonstrated significant group differences in 
[11C]DTBZ binding in the sensorimotor striatum (F2,33=14.033, p<0.0001), with significant 
DA denervation in all PD patient groups compared to healthy controls (p<0.0001), 
confirming characteristic DA depletion. No significant differences between groups were 
found in the limbic striatum.
Relationship between DA, Memory, and Executive Function
Finally, we investigated whether memory performance was related to dopaminergic changes 
in the brain regions demonstrating significant changes in the amnestic PD group. A 
voxelwise linear regression analysis demonstrated a significant positive relationship between 
D2 receptor availability and memory composite z-scores in PD patients with memory 
impairment in the right PHG (R2=0.46, T=4.38; X=22, Y=−26, Z=−18; k=16, p<0.05; Fig 3) 
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and left insula (R2=0.56, T=4.26; X=−38, Y=−22, Z=2; k=56, p<0.05; see Fig 3), 
demonstrating that higher D2 availability is predictive of memory performance in PD 
patients with amnestic MCI in these regions. This was significant after the inclusion of 
executive composite z-score as a nuisance variable in the analysis, suggesting that D2 
receptor binding is independently associated with memory in these regions. There were no 
significant relationships between memory and D2 availability in any other subject group. 
Furthermore, we aimed to assess whether changes in D2 in these regions were related to 
executive dysfunction, which could potentially overlap with the neural substrates of memory 
dysfunction. There was no relationship between executive dysfunction and D2 binding levels 
in these regions in the amnestic MCI group; however, when all PD patients with MCI 
(amnestic and nonamnestic, n=19) were included, there was a significant positive 
relationship between D2 receptor binding and executive performance in the bilateral insula 
and left ACC (Fig 4). No relationship was found between [11C]DTBZ binding in the 
associative striatum and any cognitive measure.
We performed an additional cortical thickness analysis, to verify that the cortical D2 changes 
seen were not related to neuronal atrophy in PD patients. The analysis confirmed that there 
were no significant differences in cortical thickness between groups in any of our a priori 
defined regions of interest, confirming that D2 receptor measurements were not affected by 
significant neuronal loss.
Discussion
In this study, we established that memory impairment in PD is associated with a loss of 
dopaminergic function in the salience network and right PHG. PD patients with memory 
impairment demonstrated (1) significant D2 receptor reductions in the salience network 
nodes extending beyond the insula into the ACC and (2) more severe D2 reductions in the 
right PHG when compared to healthy controls and PD patients with no cognitive 
impairment. Additionally, DA D2 receptor levels in the left insula and right PHG were 
positively associated with memory performance. We found a strong correlation between D2 
receptor levels and executive performance bilaterally in the insula and in the left anterior 
cingulate, regions constituting the salience network, when including all patients with MCI. 
Furthermore, significant DA neuron degeneration was found in PD patients with both 
memory and nonmemory cognitive deficits in the associative striatum.
Reduced D2 receptor availability in the anterior cingulate in addition to the insula in patients 
with memory impairment suggests that more severe and diffuse salience network changes 
contribute to memory dysfunction. There has been a growing interest in studying large-scale 
brain networks in neurodegenerative disease due to their selective vulnerability.56 The 
salience network is crucial for switching between and causally modulating the activity of the 
reciprocally active executive and default mode networks,7,8,57,58 and is consistently engaged 
during memory retrieval.59 The medial temporal lobe including the hippocampus and PHG 
is considered a subsystem of the default mode network.60 Thus, abnormal interaction 
between the salience network and medial temporal lobe due to DA dysfunction could impact 
the relay of information required for accurate memory retrieval. It has recently been shown 
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that default mode network function relies on salience network integrity after traumatic brain 
injury, emphasizing the influence this network might have on memory.9
Reduced D2 receptor levels in the right PHG of PD patients with memory impairment are 
consistent with its known role in providing contextual information associated with memory,
61 including semantic and visuospatial memory,62–64 which were severely impaired in our 
PD amnestic MCI patient group. The PHG is the major convergence point of incoming 
cortical information to the hippocampal formation,65 and DA signaling in this region is 
involved in incorporating cortical input for memory encoding and retrieval. Furthermore, the 
salience network and PHG are structurally and functionally connected,16,17 which may be 
essential for providing information pertaining to past experiences. The salience network is 
known to process the degree of personal relevance of stimuli to direct behavior in uncertain 
situations, which involves integrating visceral and cognitive/emotional information with 
contextual information from past experience.66 Thus, a disruption in contextual input from 
the PHG to this network could impact effective utilization of memory.
Our finding of a significant correlation between executive function and D2 receptor 
availability in nodes of the salience network in all MCI patients corroborates our previous 
finding of a relationship between D2 in the right anterior insula and executive function in PD 
patients with MCI.6 In this study, we found a correlation of both executive function (all MCI 
patients) and memory (only in patients with memory impairment) with D2 receptors in 
regions of the salience network, suggesting that its function may be multipurpose. Memory 
is not process pure, and relies on executive mechanisms for encoding, coordination, and 
retrieval.12,67 Thus, a disruption of dopaminergic modulation in the salience network could 
impact switching between the central executive and default mode network required for 
mental flexibility and the coordination of memory,7 resulting in distinct associations with 
poor executive and memory performance (Fig 5). From a network perspective this is 
plausible, and well supported by the recent findings in the literature indicating that the 
salience network has a binary role in modulating both the default mode and central executive 
networks.7,8
The absence of significant atrophy and anatomical pattern of D2 receptor loss suggests that 
Lewy body deposition may be the pathological mechanism affecting D2 receptor expression. 
The pattern of deposition according to Braak’s staging hypothesis begins in the brainstem, 
and then spreads to limbic regions including the medial temporal lobe, followed by the 
insula, and temporal and anterior cingulate cortices.68 Although cortical Lewy bodies do not 
directly result in neuronal death, this pathology could have an impact on D2 receptor 
expression in different individuals with PD. Furthermore, D2 receptor loss has been 
associated with disease severity in PD.69 Although we controlled for motor disease severity 
in the analyses, there may be an inevitable link between regional pathological progression 
and cognitive decline.
There were no significant changes in the hypothesized DLPFC or PPC of the executive 
network. Although it appears that D2 binding may be slightly lower than controls in both 
MCI groups, it cannot differentiate patient groups. This could be due to D2 receptor levels in 
these regions being less vulnerable to pathology affecting D2 receptor expression, such as 
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Lewy body deposition. The medial temporal lobe and salience network may be also be 
affected earlier by a loss of D2, resulting in dysfunction of these regions in cognitive 
processes. As previously mentioned, the salience network plays a crucial role in engaging 
the central executive network, and therefore abnormalities in this network may disrupt 
executive mechanisms in PD, despite the lack of significant change in D2 receptor binding 
within the central executive network.
It is worth noting that a pathological loss of other receptor types, such as the D1 receptor, 
might occur in parallel to a loss of D2 receptors. Because D1 and D2 receptors act 
dynamically to perpetuate and reset cortical activity during cognitive tasks,70 a reduction in 
these receptors would have profound effects on performance in PD. Additionally, the loss of 
D2 receptors could have interactions with other affected neurotransmitter systems and PD-
related pathology. For example, although the evidence regarding a link between amyloid and 
cognition in PD has been inconclusive, it has been associated with future cognitive decline, 
although not correlating directly with cognitive measures.71 The cholinergic system is also 
affected in PD and related to cognitive impairment. The cholinergic system has significant 
interactions with the dopaminergic system, and reduced cholinergic signaling has been 
associated with reducing dopaminergic function. 72 Therefore, the combined effect of a loss 
of function in these neurotransmitter systems could contribute to cognitive deficits seen in 
PD.
Our findings provide novel insight into the mechanism of memory impairment in PD. PD 
patients frequently experience difficulty recalling past information or events.73 The salience 
network and the parahippocampal gyrus are consistently engaged during memory retrieval, 
and thus our findings are consistent with the functional role of these regions. Additionally, 
the salience network being affected may impair switching between networks (central 
executive network and default mode network), resulting in patients becoming stuck, that is, 
unable to retrieve information pertaining to past experiences to be used for executive tasks 
(see Fig 5). Based on our findings, it seems likely that there are not completely distinct 
pathways for amnestic and nonamnestic MCI, but rather a more profound spread of D2 
reductions in the medial temporal lobe and within the salience network affecting retrieval of 
information from long-term memory.
In conclusion, these results suggest that memory deficits in PD are associated with abnormal 
dopaminergic function in large-scale cortical networks involved in accessing memory, as 
well as disrupted DA signaling in the medial temporal lobe. Furthermore, aberrant relay 
between the PHG and salience network involved in providing contextual information to 
guide memory use may impact both memory and executive performance. Our findings 
demonstrate the vulnerability of the salience network and the PHG to dopaminergic changes 
in PD in the absence of atrophic changes, and specifically highlight the potential impact on 
memory function. Future investigations should focus on the salience network as a key 
vulnerable network, as well as the role of the PHG in memory decline in PD.
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Refer to Web version on PubMed Central for supplementary material.
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Statistical parametric maps of regions of reduced D2 receptor availability in Parkinson 
disease (PD) with amnestic mild cognitive impairment (MCI; top) and nonamnestic MCI 
(bottom) compared to PD patients with no MCI (cognitively normal). Blue circles (top) 
indicate regions of the salience network (bilateral insula and left anterior cingulate cortex), 
as well as the right parahippocampal gyrus. Color scales represent T value.
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Group differences in [11C]dihydrotetrabenazine (DTBZ) binding in the associative striatum, 
demonstrating a downward trend in binding from healthy to Parkinson disease (PD) with 
amnestic mild cognitive impairment (MCI). Bars represent group means. Error bars 
represent standard error of the mean. *p=0.005, **p < 0.0001, ***p=0.016. 
BPND=nondisplaceable binding potential. [Color figure can be viewed in the online issue, 
which is available at www.annalsofneurology.org.]
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Statistical map of voxels significantly associated with memory composite z-scores. Mean 
[11C]FLB nondisplaceable binding potential (BPND) values were extracted from a 6mm 
radius sphere within the parahippocampal gyrus and left insula and plotted to show the 
relationship between D2 receptor binding and memory performance in Parkinson disease 
patients with amnestic mild cognitive impairment.
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Statistical map of voxels significantly associated with executive composite z-scores. Mean 
[11C]FLB nondisplaceable binding potential (BPND) values were extracted from a 6mm 
radius sphere within the significant clusters and plotted to show the relationship between D2 
receptor binding and executive performance in Parkinson disease patients with mild 
cognitive impairment (amnestic and nonamnestic).
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Conceptual diagram demonstrating networks with reduced D2 receptor (R) binding in 
Parkinson disease (PD) with mild cognitive impairment and the potential impact on network 
interactions affecting memory and executive function. Reduced D2 in the salience network 
could impair engagement of the central executive network (CEN), and switching between 
the default mode network (DMN) and CEN. Reduced D2 in the medial temporal lobe (MTL) 
could disrupt the use of contextual information related to memory that is accessed by the 
salience network.
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TABLE 1
Demographic and Clinical Variables
Variable HC, n =14 PD No MCI, n =11 PD naMCI, n =10 PD aMCI, n =9
Age, yr 67.5 (5.35) 68.8 (3.71) 70.2 (8.27) 68.3 (7.40)
Education, yr 17.1 (2.74) 15.7 (2.87) 16.7 (1.12) 16.6 (1.94)
M/F 3/11 3/8 7/3 7/2
MoCA 27.6 (2.21) 26.5 (1.81) 24.0 (2.12)a 21.9 (3.40)b
BDI 4.0 (3.96) 5.91 (1.87) 4.89 (3.89) 5.78 (6.0)
UPDRS-III — 23.3 (12.03) 20.8 (12.86) 36.1 (16.0)
Disease duration, yr — 6.32 (4.20) 6.11 (3.10) 6.11 (2.85)
LEDD total, mg/day — 725 (570.85) 611.17 (437.85) 577.98 (245.0)
Values are listed as mean (standard deviation).
a
The nonamnestic PD-MCI group had significantly lower MoCA scores compared to patients with no MCI (p = 0.004) and healthy controls (p = 
0.0003).
b
The amnestic PD-MCI group had significantly lower MoCA scores compared to PD patients with no MCI (p = 0.001) and healthy controls (p < 
0.0001). There were no significant differences in age, education, UPDRS-III, LEDD, or BDI between groups.
aMCI =amnestic MCI; BDI =Beck Depression Inventory; F =female; HC =healthy controls; LEDD =L-dopa equivalent daily dose (calculated 
according to Evans et al21); M =male; MCI =mild cognitive impairment; MoCA =Montreal Cognitive Assessment; naMCI =nonamnestic MCI; PD 
=Parkinson disease; UPDRS-III =Unified Parkinson Disease Rating Scale III.
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TABLE 2
Neuropsychological Data
Measure HC, n =14 PD No MCI, n =11 PD naMCI, n =10 PD aMCI, n =9
Digit Span forward 0.53 (1.04) 0.56 (0.50) 0.04 (0.88) −0.26 (0.54)
CVLT delayed free recall 0.25 (0.92) 0.54 (0.72) −0.45 (1.01) −1.17 (0.94)a,b
Letter-Number Sequencing 0.15 (0.68) 0.30 (0.64) 0.27 (0.93) −0.41 (0.72)
Visual Verbal total shifts −0.4 (0.49) −1.38 (2.03) −3.34 (1.77)a,b −2.74 (1.43)a,b
JLO total correct 0.14 (0.84) −0.07 (1.23) −1.57 (1.78)a −2.03 (1.13)a,b
Color-Word: color naming, completion time 0.4 (0.91) 0.12 (0.54) −0.27 (0.66) −0.98 (1.36)
Color-Word: inhibition, completion time 0.33 (1.02) 0.30 (0.71) 0.01 (0.59) −0.67 (0.78)
Category fluency 0.85 (0.89) 0.95 (0.96) −0.73 (1.01)a −0.46 (1.19) a,b
RCFT copy score — −0.15 (0.47) −1.20 (1.36) −1.28 (1.37)
RCFT delayed recall — 0.90 (1.49) 0.45 (1.10) −2.07 (0.34)b,c
Trail-Making Test, difference score — 0.08 (1.00) −0.67 (1.32) −2.48 (2.27)b
Boston Naming Test — 0.76 (0.50) 0.45 (0.69) 0.48 (1.31)
Memory composite z score 0.23 (0.92) 0.68 (0.83) 0.002 (0.71) −1.60 (0.42)a,c
Executive composite z score 0.26 (0.62) 0.044 (0.35) −1.16 (0.54)a,b −1.64 (1.07)a,b
Values are listed as group-based mean z scores (standard deviation).
a
Significantly lower than HC.
b
significantly lower than PD no MCI.
c
significantly lower than PD naMCI, p < 0.05.
aMCI =amnestic MCI; CVLT =California Verbal Learning Test; HC =healthy controls; JLO =Judgment of Line Orientation; MCI =mild cognitive 
impairment; naMCI =nonamnestic MCI; PD =Parkinson disease; RCFT =Rey Complex Figure Test.
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TABLE 3
Mean [11C]FLB 457 BPND Extracted from Cortical ROIs
Region HC, n =14 PD No MCI, n =11 PD naMCI, n =10 PD aMCI, n =9
Left DLPFC 0.35 (0.09) 0.32 (0.05) 0.09 (0.09) 0.12 (0.07)
Right DLPFC 0.30 (0.10) 0.24 (0.17) 0.01 (0.08) 0.02 (0.08)
Left parietal 0.48 (0.12) 0.39 (0.16) 0.16 (0.09) 0.17 (0.07)
Right parietal 0.38 (0.10) 0.27 (0.15) 0.01 (0.09) 0.03 (0.09)
Left MTL 0.94 (0.11) 0.78 (0.07) 0.65 (0.09) 0.47 (0.07)
Right MTLa 1.13 (0.11) 0.93 (0.12) 0.80 (0.10) 0.57 (0.20)
Left insulaa 1.00 (0.20) 0.81 (0.36) 0.62 (0.06) 0.44 (0.08)
Right insulaa 1.04 (0.21) 0.84 (0.21) 0.52 (0.08) 0.39 (0.07)
Left ACCa 0.79 (0.15) 0.74 (0.20) 0.67 (0.10) 0.40 (0.09)
Right ACCa 0.80 (0.12) 0.86 (0.31) 0.56 (0.08) 0.45 (0.09)
Values are listed as group-based mean (standard error).
a
Indicates ROIs where significant changes were detected in the voxel-based group comparisons.
ACC =anterior cingulate cortex; aMCI =amnestic MCI; BPND = nondisplaceable binding potential; DLPFC =dorsolateral pre-frontal cortex; HC 
=healthy controls; MCI =mild cognitive impairment; MTL =medial temporal lobe; naMCI =nonamnestic MCI; PD =Parkinson disease; ROI 
=region of interest.
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